As of September 29, 2026, the three largest insider holders of MEDS are Prashant Patel (Chief Executive Officer, 282.37K shares), Surendra K Ajjarapu (Director, 257.64K shares), Surendra K Ajjarapu (Director, 187.71K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Surendra K Ajjarapu | Director | 294,090 | 151,264 | 445,354 | 42.1% | 25 Jun, 2026 |
| 2 | Prashant Patel | Chief Executive Officer | 364,730 | 44,000 | 408,730 | 38.7% | 25 Jun, 2026 |
| 3 | Brian Norton | Chief Executive Officer | 180,894 | 0 | 180,894 | 17.1% | 25 Mar, 2025 |
| 4 | Rebecca M Shanahan | Director | 4,894 | 0 | 4,894 | 0.5% | 25 Mar, 2025 |
| 5 | Donald William Anderson | Director | 4,894 | 0 | 4,894 | 0.5% | 25 Mar, 2025 |
| 6 | Sajid Syed | Director | 4,894 | 0 | 4,894 | 0.5% | 25 Mar, 2025 |
| 7 | Michael L Peterson | Director | 4,000 | 0 | 4,000 | 0.4% | 08 Jul, 2025 |
| 8 | Shafaat Pirani | Chief Clinical Officer | 2,042 | 0 | 2,042 | 0.2% | 25 Mar, 2025 |
| 9 | Nikul Panchal | Chief Pharmacy Officer | 0 | 1,800 | 1,800 | 0.2% | 25 Mar, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 22 Jun, 2026 | Prashant Patel | Chief Executive Officer | Acquired X | 100,000 | $0.01 | $500 | 282,365 | Direct |
| 22 Jun, 2026 | Surendra K Ajjarapu | Director | Acquired X | 100,000 | $0.01 | $500 | 257,645 | Direct |
| 22 Jun, 2026 | Surendra K Ajjarapu | Director | Acquired X | 100,000 | $0.00 | $0 | 0 | Direct |
| 22 Jun, 2026 | Prashant Patel | Chief Executive Officer | Acquired X | 100,000 | $0.00 | $0 | 0 | Direct |
| 31 Mar, 2026 | Surendra K Ajjarapu | Director | Acquired A | 5,000,000 | $10.00 | $50.00Mn | 157,645 | Direct |
| 31 Mar, 2026 | Prashant Patel | Chief Executive Officer | Acquired A | 5,000,000 | $10.00 | $50.00Mn | 182,365 | Direct |
| 31 Mar, 2026 | Prashant Patel | Chief Executive Officer | Acquired A | 5,000,000 | $0.50 | $2.50Mn | 100,000 | Direct |
| 31 Mar, 2026 | Surendra K Ajjarapu | Director | Acquired A | 5,000,000 | $0.50 | $2.50Mn | 100,000 | Direct |
| 02 Jul, 2025 | Michael L Peterson | Director | Disposed A | 200,000 | $45.00 | $9.00Mn | 4,000 | Direct |
| 21 Mar, 2025 | Surendra K Ajjarapu | Director | Acquired A | 2,882,247 | $0.00 | $0 | 36,445 | Direct |
| 21 Mar, 2025 | Rebecca M Shanahan | Director | Acquired A | 200,000 | $0.00 | $0 | 4,894 | Direct |
| 21 Mar, 2025 | Prashant Patel | Chief Strategy Officer | Acquired A | 1,882,247 | $0.00 | $0 | 82,365 | Direct |
| 21 Mar, 2025 | Donald William Anderson | Director | Acquired A | 200,000 | $0.00 | $0 | 4,894 | Direct |
| 21 Mar, 2025 | Sajid Syed | Director | Acquired A | 200,000 | $0.00 | $0 | 4,894 | Direct |
| 21 Mar, 2025 | Shafaat Pirani | Chief Clinical Officer | Acquired A | 35,000 | $0.00 | $0 | 2,042 | Direct |
| 21 Mar, 2025 | Brian Norton | Chief Executive Officer | Acquired A | 9,000,000 | $0.00 | $0 | 180,894 | Direct |
| 21 Mar, 2025 | Surendra K Ajjarapu | Director | Acquired A | 600,000 | $0.00 | $0 | 89,264 | Indirect |
| 21 Mar, 2025 | Prashant Patel | Chief Strategy Officer | Acquired A | 1,500,000 | $0.00 | $0 | 30,000 | Indirect |
| 21 Mar, 2025 | Nikul Panchal | Chief Pharmacy Officer | Acquired A | 90,000 | $0.00 | $0 | 1,800 | Indirect |
| 21 Mar, 2025 | Surendra K Ajjarapu | Director | Acquired A | 600,000 | $0.00 | $0 | 62,000 | Indirect |